Vandana G Abramson

15PUBLICATIONS
119CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 03, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.

Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter

|Jul 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Adrienne G Waks, Emily L Chen, Noah Graham

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Apr 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.

Elizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson

|Oct 04, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.

Brandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson

|Dec 10, 2022
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.

Eric M Lander, Katherine C Rappazzo, Li-Ching Huang

Pageof 3

Frequent Collaborators

6 joint publications

Eric Winer

5 joint publications

Ian Krop

5 joint publications

Antonio C Wolff

4 joint publications

Mothaffar Rimawi